Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye cancer survivors: does anesthesia affect the brain?

NCT ID NCT06227962

Knowledge-focused Sponsor: Amsterdam University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how cancer treatment and multiple rounds of anesthesia affect thinking skills, emotions, and quality of life in people who survived retinoblastoma (a rare eye cancer) or were at risk for it. Researchers will test memory, attention, and other brain functions in 240 participants aged 8 to 35. The goal is to understand long-term effects, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 350 Rb survivors and 310 Rb risk carriers (\<35 years) that have been treated or screened at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center

Ages

6 months to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Rb survivors and Rb risk carriers (age 8-35 years): * Rb diagnosis, (main) treatment and follow-up of Rb patients and -survivors, or Rb screening took place at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center, * Rb survivor or former Rb risk carriers is between 8 and 35 years old, * Average understanding of the Dutch language. Inclusion Criteria parents of Rb patients, Rb survivors or Rb risk carriers (6 months - 12 years): * Being a caregiver of a Rb survivor or Rb risk carrier that have been diagnosed and receive(d) (main) treatment and follow-up or screening at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center, * The related Rb survivor or Rb risk carrier is \< 12 years old, * Average understanding of the Dutch language. Exclusion Criteria: * Pre-existing documented developmental delay and/or severe cognitive impairments (IQ \<70), * Having an active, uncontrolled psychiatric illness, * Rb diagnostic trajectory, treatment and follow-up at another hospital or before the founding of the Dutch Retinoblastoma Expertise Center in 1991. With exception of Rb survivors (diagnosed \>1991) who apart from treatment at the Dutch Retinoblastoma Center also required specialized treatment (such as radiation) at another center: they are illegible for inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Health-related behavior are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognition Disorders cognitive disorder Health Behavior retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Health-related behavior Neurocognitive dysfunction Retinoblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    Amsterdam, North Holland, 1081 HZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.